Drug resistance interpretation: RT — HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None
NNRTI Mutations: None
RT Other Mutations: P1T • I2H • S3Q • P4R • I5F • E6N • T7M • V8P • V35T • E40D • K49R • V60I • D121H • K122E • I135T • I142V • K173S • Q174K • D177E • T200I • L205V • R206K • Q207E • R211K • P226S • Y232M • Δ233 • L234S • H235S • P236S • P243L • I244* • V245T • L246A • P247D • E248K • D250L • S251T • W252V • T253M • V254I • N255Y

Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Susceptible
efavirenz (EFV)	Susceptible
etravirine (ETR)	Susceptible
nevirapine (NVP)	Susceptible
rilpivirine (RPV)	Susceptible

RT comments

Other

- L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been well characterized. **L234S** is a highly unusual mutation at this position.
- P236L is a rare mutation selected commonly by DLV, which appears to have little if any effect on current NNRTIs. **P236S** is a highly unusual mutation at this position.

Mutation scoring: RT — HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.